Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings Plc LSE:COG London Ordinary Share GB00B8DV9647 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 79.50 79,532 08:00:27
Bid Price Offer Price High Price Low Price Open Price
77.00 82.00 82.00 79.50 79.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 5.04 -3.12 -12.40 25
Last Trade Time Trade Type Trade Size Trade Price Currency
16:13:03 O 15,000 80.00 GBX

Cambridge Cognition (COG) Latest News

More Cambridge Cognition News
Cambridge Cognition Investors    Cambridge Cognition Takeover Rumours

Cambridge Cognition (COG) Discussions and Chat

Cambridge Cognition Forums and Chat

Date Time Title Posts
19/1/202107:27Cambridge Cognition Holdings (COG)204
13/5/201910:12Dementia - Computerised Neuropsychological Testing177
30/4/201921:22Cambridge Cognition at UK Investor Show1
02/9/201714:05COG with Charts & News63

Add a New Thread

Cambridge Cognition (COG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-22 17:13:0480.0015,00012,000.00O
2021-01-22 15:35:3778.152,0001,563.00O
2021-01-22 14:01:5478.15234182.87O
2021-01-22 13:57:0681.153,2502,637.38O
2021-01-22 13:34:4381.156,1524,992.35O
View all Cambridge Cognition trades in real-time

Cambridge Cognition (COG) Top Chat Posts

DateSubject
22/1/2021
08:20
Cambridge Cognition Daily Update: Cambridge Cognition Holdings Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker COG. The last closing price for Cambridge Cognition was 79.50p.
Cambridge Cognition Holdings Plc has a 4 week average price of 57.50p and a 12 week average price of 52p.
The 1 year high share price is 82p while the 1 year low share price is currently 18p.
There are currently 31,170,093 shares in issue and the average daily traded volume is 128,073 shares. The market capitalisation of Cambridge Cognition Holdings Plc is £24,780,223.94.
13/1/2021
23:39
40 fathoms: Not a chance Cogstate are involved in my view. You go to Cogstate for an excellent commercial/commodity type offering. You go to COG for complex/bespoke research projects exploring leading edge ideas that require analysis and insight. With this large, multi-year, research driven project, COG would be the only commercial group qualified in my view. The reason I suspect COG are involved can be seen from looking at the linkedin page of Biogen's Matt Hobbs, who moved across from COG last year. With no disrespect intended to the excellent scientific team at Cogstate, when it comes to innovation they are not a patch on the COG team (Pam Ventola is a possible exception). For example COG are still researching their voice based products and are probably still at least 24 months away from having a validated product, COG are already in the market and getting paid with their voice project. If we move on to other aspects such as wareables, social cognition, digital phenotyping etc, COG are so far ahead of Cogstate it is not even really open for debate. Where Cogstate are (have been) much stronger than COG is with commercialisation and they continue to do an excellent job at that. However their commercial focus also means they only purse areas where they can get paid at scale rather than one off bespoke projects.
13/1/2021
11:03
40 fathoms: Biogen, Apple to launch virtual study on cognitive decline The research project will be conducted using the Apple Watch and iPhone, and is set to begin during 2021. COG lead the world in this area digital wearables and are the only ones I know off who have previously used apple watches in trials to measure cognition. I reckon there has to be a very good chance that they are involved in this project.
25/11/2020
23:29
40 fathoms: I am assuming you are talking about AD in a healthcare context ? I don't think it will have any impact what so ever as the article itself says it is seen as complementary to cognitive testing not a replacement. Firstly as a triage tool and from a price and ease of administration viewpoint you will never beat a digital test costing a few US$. Secondly, even if you can detect beta amyloid in the blood you will still need to monitor and assess the cognitive impact, which will very greatly amongst patients and that can only be done by cognitive testing. Finally, at present this is a tiny part of COGs business and even if this was (and it wont) to close the triage AD market to COG there a large number of other health care applications for their various tests. If it has any negative impact it would be more for a company like IXICO, if they were ever to move in to the healthcare setting.
11/11/2020
22:26
mm84: Hey guys, what if Cogstate buys COG?
08/11/2020
18:20
stevee1234: 40F, I have to admit that the FDA briefing note taxed my endurance (121 pages plus figures) but as you say the FDA are extremely positive and clearly from cog's reported view from October 2019 they see it as a massive opportunity. Thanks for posting all this on the board. It really does appear from this and other opportunities that cog are in a very good place for future significant growth over the short to medium term. S
06/11/2020
13:39
40 fathoms: hxxps://www.sharecast.com/news/aim-bulletin/cambridge-cognition-hoping-to-ride-coat-tails-of-biogen-alzheimers-programme--7093535.html This was from COG last year on the issue.
06/11/2020
12:40
40 fathoms: Stevee, just as a reminder the approval of Aducanumab would not in itself be a direct benefit to COG. They were not involved in the trial and have no link to Biogen or Eisai. However, what it does mean is that with a disease modifying drug on the market, GPs need a quick and cheap way to work out if a persons memory is normal and if they should be passed on to a specialist. GPs have neither the time, training nor resources to do this via old fashioned pencil and paper methods. There are only 3, possibly 4, companies globally that offer a regulatory approved, validated, cloud-based test that you can conduct (without supervision) on a tablet or a PC. COG is one of those 3. I have no doubt as we speak management is discussions with all sorts of parties about offering this test if Aducanumab is approved. So the FDA must give a decision by March, if approved the drug will be available from next summer. It seems highly likely to me that if it looks like it will get approved you will see COG starting to sign deals end of this year early next.
26/10/2020
08:04
stevee1234: 40F something similar for cog would indeed be transformational for the share price. My fingers and toes are crossed in hope, also a fair degree of confidence significant deals will be announced over time.
26/10/2020
06:15
40 fathoms: Today Eisai just paid a minimum of US$ 45 million (US$ 15 million upfront) for a 10 year licence with royalties to use Cogstate’s Cognigram product in healthcare. Given our significant advantages over Cognigram and the distinct lack of validated competition in this space, there is no reason why there is not a similar sort of deal somewhere out there for us. Imagine what our share price would do if we had announced a similar deal today. On a slightly different note I think it is interesting that Eisai did this deal prior to the November 6th FDA advisory committee steer on Aducanumab, given they are the junior partner to Biogen for this drug.
07/10/2020
12:22
40 fathoms: What is interesting is they get to keep their IP for much of the bespoke and market leading work that they do on behalf of Pharma. This can then be offered to other clients. Nice work if you can get it. This business is grossly undervalued. That is before you even consider a possible positive FDA decision on Aducanumab (pdufa date 7 March 2021), if we get a positive outcome you will see a truly huge step change in the commercial potential for the business. There are only 3 or 4 companies that can offer regulatory approved, highly sensitive, digital administered cognitive test capable of triaging potential Alzheimers patients. Pick your price per test multiply by the tens of millions of tests that will be administered every year, assign COG with a share of those tests. In the context of an already profitable business with a 15 million market cap even crumbs from this will be business changing.
Cambridge Cognition share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
COG
Cambridge ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210123 02:50:05